AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
INmune Bio Reports New Phase 2 Grey Matter Imaging Data Reinforcing XPro1595's Potential in Alzheimer's Patients
ByAinvest
Monday, Dec 1, 2025 8:02 am ET1min read
INmune Bio reports new Phase 2 grey matter imaging data from its MINDFuL trial of XPro1595 in early Alzheimer's disease patients with elevated neuroinflammation. The results show a trend towards slowed neurodegeneration progression and reinforce the drug's mechanism of selectively neutralizing soluble TNF. The data further validate INmune Bio's strategy of targeting inflammation-driven AD, a large unmet need and potential commercial opportunity.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet